866-997-4948(US-Canada Toll Free)

Lupron Depot (Prostate Cancer) - Forecast and Market Analysis to 2022

Published By :


Published Date : Dec 2012

Category :


No. of Pages : 49 Pages

Lupron Depot (Prostate Cancer) - Forecast and Market Analysis to 2022


GlobalData has released its new PharmaPoint Drug Evaluation report, “Lupron Depot (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. 

For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Abbott’s and Takeda’s Lupron Depot is a subcutaneously- or intramuscularly-delivered GnRH analogue used to treat advanced androgen-dependent prostate cancers. It was originally developed by TAP Pharmaceuticals, a now-dissolved collaboration between Abbott and Takeda. 

It is currently marketed by Abbott in the US, Canada, and Australia, and by Takeda in the 5EU and Japan. Lupron Depot is classified as an LHRH receptor agonist, which binds to the LHRH receptor and prevents the pituitary gland from secreting luteinizing hormone. 

Luteinizing hormone stimulates the testes to produce testosterone, and consequently LHRH analogs are commonly used in ADT regimens for the treatment of prostate cancer. Leuprolide acetate, the active ingredient in Lupron Depot, is encapsulated in polylactic acid microspheres that biodegrade and slowly release leuprolide acetate (TGA, 2010).

  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Lupron Depot including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Lupron Depot for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia 
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Lupron Depot performance 
  • Obtain sales forecast for Lupron Depot from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.1.3 Prognosis 12
3.1.4 Quality of Life 13
3.2 Symptoms 14

4 Disease Management 15
4.1 Diagnosis and Referral Overview 15
4.2 Treatment Overview 17
4.2.1 Conservative Management Strategies 21
4.2.2 Localized Treatments 22
4.2.3 Hormone Therapy 23
4.2.4 Drug Therapies 25

5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28

6 Lupron Depot (leuprolide acetate) 31
6.1 Overview 31
6.2 Efficacy 32
6.3 Safety 33
6.4 SWOT Analysis 33
6.5 Forecast 35

7 Appendix 36
7.1 Bibliography 36
7.2 Abbreviations 40
7.3 Methodology 42
7.4 Forecasting Methodology 42
7.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 42
7.4.2 Percent Drug-Treated Patients 43
7.4.3 Percent Hormone Therapy-Treated Patients 43
7.4.4 General Pricing Assumptions 43
7.4.5 Individual Drug Assumptions 45
7.4.6 Generic Erosion 46
7.5 Physicians and Specialists Included in This Study 46
7.6 Survey of Prescribing Physicians 47
7.7 About the Authors 47
7.7.1 Authors 47
7.7.2 Global Head of Healthcare 48
7.8 About GlobalData 49
7.9 Contact Us 49
7.10 Disclaimer 49

List of Table

Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 13
Table 2: Global Variations in Recommendations on Routine PSA Screening 15
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 18
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 20
Table 5: Leading Treatments for Prostate Cancer, 2012 30
Table 6: Product Profile - Lupron Depot 32
Table 7: Lupron Depot SWOT Analysis, 2012 34
Table 8: Global Sales Forecasts ($) for Lupron Depot, 2012-2022 35
Table 9: Physicians Surveyed, By Country 47

List of Chart

Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 19

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *